XNAS 04 May, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2026 | 3,542 | 155,833 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 23 Apr 2026 | 3,542 | 36,575 | - | 4.4 | 15,514 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 5,437 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 3,383 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 01 Apr 2026 | 5,437 | 5,437 | - | 4.1 | 22,346 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 01 Apr 2026 | 3,383 | 8,820 | - | 6.6 | 22,226 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 01 Apr 2026 | 8,820 | 0 | - | 17.8 | 157,084 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 2,000 | 3,383 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 02 Mar 2026 | 7,433 | 0 | - | 20.3 | 150,890 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 5,433 | 5,437 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 02 Mar 2026 | 5,433 | 5,433 | - | 4.1 | 22,330 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Mar 2026 | 2,000 | 7,433 | - | 6.6 | 13,140 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 01 Mar 2026 | 3,542 | 33,033 | - | 4.4 | 15,514 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 3,542 | 159,375 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Shane Barton | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 330,000 | 330,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Feb 2026 | 2,000 | 7,433 | - | 6.6 | 13,140 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.75 per share. | 02 Feb 2026 | 7,433 | 0 | - | 18.8 | 139,369 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 5,433 | 10,870 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 02 Feb 2026 | 5,433 | 5,433 | - | 4.1 | 22,330 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 2,000 | 5,383 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 3,541 | 162,917 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 01 Feb 2026 | 3,541 | 29,491 | - | 4.4 | 15,510 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 16 Jan 2026 | 3,542 | 25,950 | - | 4.4 | 15,514 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2026 | 3,542 | 166,458 | - | - | Stock Option (Right to Buy) | |
| Kristen Fortney | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.12 per share. | 13 Jan 2026 | 233,107 | 976,949 | - | 18.1 | 4,223,036 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.39 per share. | 13 Jan 2026 | 27,000 | 49,408 | - | 8.4 | 226,530 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 13 Jan 2026 | 4,440 | 35,994 | - | 19.5 | 86,370 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.54 per share. | 13 Jan 2026 | 11,663 | 24,331 | - | 20.5 | 239,549 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.08 per share. | 13 Jan 2026 | 1,923 | 22,408 | - | 21.1 | 40,538 | Common Stock |
| Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 27,000 | 92,587 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.43 per share. | 13 Jan 2026 | 8,974 | 40,434 | - | 18.4 | 165,371 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 02 Jan 2026 | 5,433 | 5,433 | - | 4.1 | 22,330 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 2,000 | 7,383 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 5,433 | 16,303 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.85 per share. | 02 Jan 2026 | 7,433 | 0 | - | 12.8 | 95,490 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Jan 2026 | 2,000 | 7,433 | - | 6.6 | 13,140 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 09 Dec 2025 | 18,000 | 18,000 | - | 6.6 | 118,260 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 09 Dec 2025 | 18,000 | 0 | - | 12 | 216,000 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 18,000 | 9,383 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 04 Dec 2025 | 68,897 | 68,897 | - | 4.1 | 283,167 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.19 per share. | 04 Dec 2025 | 68,897 | 0 | - | 10.2 | 701,909 | Common Stock |
| Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 68,897 | 21,736 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Garnier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Dov A. Goldstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Rubin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 530,000 | 530,000 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Shane Barton | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Patrick G. Enright | Director | 25 Sep 2024 | 5,848,637 | 0 | - | - | Series D Preferred Stock | ||
| Patrick G. Enright | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 400,000 | 1,710,589 | - | 18 | 7,200,000 | Common Stock |
| Patrick G. Enright | Director | 25 Sep 2024 | 1,310,589 | 1,310,589 | - | - | Common Stock | ||
| James I. Healy | Director | 25 Sep 2024 | 1,638,236 | 1,638,236 | - | - | Common Stock | ||
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 11,113 | 11,113 | - | 18 | 200,034 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 588,888 | 2,227,124 | - | 18 | 10,599,984 | Common Stock |
| James I. Healy | Director | 25 Sep 2024 | 7,310,796 | 0 | - | - | Series D Preferred Stock | ||
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 18,353 | 18,353 | - | 18 | 330,354 | Common Stock |
| James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 26,497 | 26,497 | - | 18 | 476,946 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 21,814 | 21,814 | - | 18 | 392,652 | Common Stock |
| Jean-Pierre Garnier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Garnier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 141,609 | 141,609 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 28,497 | 28,497 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 424,827 | 424,827 | - | - | Stock Option (Right to Buy) | |
| Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 708,044 | 708,044 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 4,952 | 4,952 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 257,973 | 257,973 | - | - | Stock Option (Right to Buy) | |
| Eric Morgen | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 13,598 | 13,598 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 17 Apr 2024 | 3,000 | 3,000 | - | 18 | 54,000 | Common Stock |
| Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 33,986 | 33,986 | - | - | Stock Option (Right to Buy) |